Alpha₁‑adrenoreceptor antagonist

↑Alfuzosin

Increased plasma concentrations of alfuzosin may lead to severe hypotension and is therefore contraindicated (see section 4.3).

↑Tamsulosin

Tamsulosin is extensively metabolized, mainly by CYP3A4 and CYP2D6, both of which are inhibited by ritonavir. Avoid concomitant use with Paxlovid.

Amphetamine derivatives

↑Amphetamine

Ritonavir dosed as an antiretroviral agent is likely to inhibit CYP2D6 and as a result is expected to increase concentrations of amphetamine and its derivatives. Careful monitoring of adverse effects is recommended when these medicines are coadministered with Paxlovid.

Analgesics

↑Buprenorphine (57%, 77%)

The increases of plasma levels of buprenorphine and its active metabolite did not lead to clinically significant pharmacodynamic changes in a population of opioid tolerant patients. Adjustment to the dose of buprenorphine may therefore not be necessary when the two are dosed together.

↑Fentanyl,

↑Oxycodone

Ritonavir inhibits CYP3A4 and as a result is expected to increase the plasma concentrations of these narcotic analgesics. If concomitant use with Paxlovid is necessary, consider a dosage reduction of these narcotic analgesics and closely monitor therapeutic and adverse effects (including respiratory depression). Refer to the individual SmPCs for more information.

↓Methadone (36%, 38%)

Increased methadone dose may be necessary when coadministered with ritonavir dosed as a pharmacokinetic enhancer due to induction of glucuronidation. Dose adjustment should be considered based on the patient’s clinical response to methadone therapy.

↓Morphine

Morphine levels may be decreased due to induction of glucuronidation by coadministered ritonavir dosed as a pharmacokinetic enhancer.

↑Pethidine

Coadministration could result in increased or prolonged opioid effects. If concomitant use is necessary, consider dosage reduction of pethidine. Monitor for respiratory depression and sedation.

↓Piroxicam

Decreased piroxicam exposure due to CYP2C9 induction by Paxlovid.

Antianginal

↑Ranolazine

Due to CYP3A inhibition by ritonavir, concentrations of ranolazine are expected to increase. The concomitant administration with ranolazine is contraindicated (see section 4.3).

Antiarrhythmics

↑Amiodarone

↑Flecainide

Given the risk of substantial increase in amiodarone or flecainide exposure and thus of its related adverse events, coadministration should not be used unless a multidisciplinary consultation could be obtained to safely guide it.

↑Digoxin

This interaction may be due to modification of P-gp mediated digoxin efflux by ritonavir dosed as a pharmacokinetic enhancer. Digoxin drug concentration is expected to increase. Monitor digoxin levels if possible and digoxin safety and efficacy.

↑Disopyramide

Ritonavir may increase plasma concentrations of disopyramide which could result in an increased risk of adverse events such as cardiac arrhythmias. Caution is warranted and therapeutic concentration monitoring is recommended for disopyramide if available.

↑Dronedarone,

↑Propafenone,

↑Quinidine

Ritonavir coadministration is likely to result in increased plasma concentrations of dronedarone, propafenone and quinidine and is therefore contraindicated (see section 4.3).

Antiasthmatic

↓Theophylline (43%, 32%)

An increased dose of theophylline may be required when coadministered with ritonavir, due to induction of CYP1A2.

Anticancer agents

↑Abemaciclib

Serum concentrations may be increased due to CYP3A4 inhibition by ritonavir. Coadministration of abemaciclib and Paxlovid should be avoided. If this coadministration is judged unavoidable, refer to the abemaciclib SmPC for dosage adjustment recommendations. Monitor for ADRs related to abemaciclib.

↑Afatinib

Serum concentrations may be increased due to Breast Cancer Resistance Protein (BCRP) and acute P-gp inhibition by ritonavir. The extent of increase in AUC and C_max depends on the timing of ritonavir administration. Caution should be exercised in administering afatinib with Paxlovid (refer to the afatinib SmPC). Monitor for ADRs related to afatinib.

↑Apalutamide

Apalutamide is a moderate to strong CYP3A4 inducer and this may lead to a decreased exposure of nirmatrelvir/ritonavir and potential loss of virologic response. In addition, serum concentrations of apalutamide may be increased when coadministered with ritonavir resulting in the potential for serious adverse events including seizure. Concomitant use of Paxlovid with apalutamide is contraindicated (see section 4.3).

↑Ceritinib

Serum concentrations of ceritinib may be increased due to CYP3A and P-gp inhibition by ritonavir. Caution should be exercised in administering ceritinib with Paxlovid. Refer to the ceritinib SmPC for dosage adjustment recommendations. Monitor for ADRs related to ceritinib.

↑Dasatinib,

↑Nilotinib,

↑Vinblastine,

↑Vincristine

Serum concentrations may be increased when coadministered with ritonavir resulting in the potential for increased incidence of adverse events.

↑Encorafenib,

↑Ivosidenib

Serum concentrations of encorafenib or ivosidenib may be increased when coadministered with ritonavir which may increase the risk of toxicity, including the risk of serious adverse events such as QT interval prolongation. Avoid coadministration of encorafenib or ivosidenib. If the benefit is considered to outweigh the risk and ritonavir must be used, patients should be carefully monitored for safety.

↑Fostamatinib

Coadministration of fostamatinib with ritonavir may increase fostamatinib metabolite R406 exposure resulting in dose-related adverse events such as hepatotoxicity, neutropenia, hypertension or diarrhoea. Refer to the fostamatinib SmPC for dose reduction recommendations if such events occur.

↑Ibrutinib

Serum concentrations of ibrutinib may be increased due to CYP3A inhibition by ritonavir, resulting in increased risk for toxicity including risk of tumour lysis syndrome. Coadministration of ibrutinib and ritonavir should be avoided. If the benefit is considered to outweigh the risk and ritonavir must be used, reduce the ibrutinib dose to 140 mg and monitor patient closely for toxicity.

↑Neratinib

Serum concentrations may be increased due to CYP3A4 inhibition by ritonavir.

Concomitant use of neratinib with Paxlovid is contraindicated due to serious and/or life-threatening potential reactions including hepatotoxicity (see section 4.3).

↑Venetoclax

Serum concentrations may be increased due to CYP3A inhibition by ritonavir, resulting in increased risk of tumour lysis syndrome at the dose initiation and during the ramp-up phase and is therefore contraindicated (see section 4.3 and refer to the venetoclax SmPC). For patients who have completed the ramp-up phase and are on a steady daily dose of venetoclax, reduce the venetoclax dose by at least 75% when used with strong CYP3A inhibitors (refer to the venetoclax SmPC for dosing instructions).

Anticoagulants

↑Apixaban

Combined P-gp and strong CYP3A4 inhibitors increase blood levels of apixaban and increase the risk of bleeding. Dosing recommendations for coadministration of apixaban with Paxlovid depend on the apixaban dose. Refer to the apixaban SmPC for more information.

↑Dabigatran (94%, 133%)*

Concomitant administration of Paxlovid is expected to increase dabigatran concentrations resulting in increased risk of bleeding. Reduce dose of dabigatran or avoid concomitant use. Refer to the dabigatran SmPC for further information.

↑Rivaroxaban (153%, 53%)

Inhibition of CYP3A and P-gp lead to increased plasma levels and pharmacodynamic effects of rivaroxaban which may lead to an increased bleeding risk. Therefore, the use of Paxlovid is not recommended in patients receiving rivaroxaban.

Warfarin,

↑↓S-Warfarin (9%, 9%),

↓↔R-Warfarin (33%)

Induction of CYP1A2 and CYP2C9 lead to decreased levels of R-warfarin while little pharmacokinetic effect is noted on S‑warfarin when coadministered with ritonavir. Decreased R-warfarin levels may lead to reduced anticoagulation, therefore it is recommended that anticoagulation parameters are monitored when warfarin is coadministered with ritonavir.

Anticonvulsants

Carbamazepine*,

Phenobarbital,

Phenytoin,

Primidone

Carbamazepine decreases AUC and C_max of nirmatrelvir by 55% and 43%, respectively. Phenobarbital, phenytoin and primidone are strong CYP3A4 inducers, and this may lead to a decreased exposure of nirmatrelvir and ritonavir and potential loss of virologic response. Concomitant use of carbamazepine, phenobarbital, phenytoin and primidone with Paxlovid is contraindicated (see section 4.3).

↑Clonazepam

A dose decrease may be needed for clonazepam when coadministered with Paxlovid and clinical monitoring is recommended.

↓Divalproex,

Lamotrigine

Ritonavir dosed as a pharmacokinetic enhancer induces oxidation by CYP2C9 and glucuronidation and as a result is expected to decrease the plasma concentrations of anticonvulsants. Careful monitoring of serum levels or therapeutic effects is recommended when these medicines are coadministered with ritonavir.

Anticorticosteroids

↑Ketoconazole (3.4-fold, 55%)

Ritonavir inhibits CYP3A-mediated metabolism of ketoconazole. Due to an increased incidence of gastrointestinal and hepatic adverse reactions, a dose reduction of ketoconazole should be considered when coadministered with ritonavir.

Antidepressants

↑Amitriptyline,

Fluoxetine,

Imipramine,

Nortriptyline,

Paroxetine,

Sertraline

Ritonavir dosed as an antiretroviral agent is likely to inhibit CYP2D6 and as a result is expected to increase concentrations of imipramine, amitriptyline, nortriptyline, fluoxetine, paroxetine or sertraline. Careful monitoring of therapeutic and adverse effects is recommended when these medicines are concomitantly administered with antiretroviral doses of ritonavir.

Anti-gout

↑Colchicine

Concentrations of colchicine are expected to increase when coadministered with ritonavir. Life-threatening and fatal drug interactions have been reported in patients treated with colchicine and ritonavir (CYP3A4 and P-gp inhibition).

Concomitant use of colchicine with Paxlovid is contraindicated (see section 4.3).

Anti-HCV

↑Glecaprevir/pibrentasvir

Serum concentrations may be increased due to P-gp, BCRP and OATP1B inhibition by ritonavir. Concomitant administration of glecaprevir/pibrentasvir and Paxlovid is not recommended due to an increased risk of ALT elevations associated with increased glecaprevir exposure.

↑Sofosbuvir/velpatasvir/

voxilaprevir

Serum concentrations may be increased due to OATP1B inhibition by ritonavir. Concomitant administration of sofosbuvir/velpatasvir/voxilaprevir and Paxlovid is not recommended. Refer to the sofosbuvir/velpatasvir/voxilaprevir SmPC for further information.

Antihistamines

↑Fexofenadine

Ritonavir may modify P-gp mediated fexofenadine efflux when dosed as a pharmacokinetic enhancer resulting in increased concentrations of fexofenadine.

↑Loratadine

Ritonavir dosed as a pharmacokinetic enhancer inhibits CYP3A and as a result is expected to increase the plasma concentrations of loratadine. Careful monitoring of therapeutic and adverse effects is recommended when loratadine is coadministered with ritonavir.

↑Terfenadine

Increased plasma concentrations of terfenadine. Thereby, increasing the risk of serious arrhythmias from this agent and therefore concomitant use with Paxlovid is contraindicated (see section 4.3).

Anti-HIV

↑Bictegravir/

↔Emtricitabine/

↑Tenofovir

Ritonavir may significantly increase the plasma concentrations of bictegravir through CYP3A inhibition. Ritonavir is expected to increase the absorption of tenofovir alafenamide by inhibition of P‑gp, thereby increasing the systemic concentration of tenofovir.

↑Efavirenz (21%)

A higher frequency of adverse reactions (e.g., dizziness, nausea, paraesthesia) and laboratory abnormalities (elevated liver enzymes) have been observed when efavirenz is coadministered with ritonavir.

↑Maraviroc (161%, 28%)

Ritonavir increases the serum levels of maraviroc as a result of CYP3A inhibition. Maraviroc may be given with ritonavir to increase the maraviroc exposure. For further information, refer to the Summary of Product Characteristics for maraviroc.

↓Raltegravir (16%, 1%)

Coadministration of ritonavir and raltegravir results in a minor reduction in raltegravir levels.

↓Zidovudine (25%, ND)

Ritonavir may induce the glucuronidation of zidovudine, resulting in slightly decreased levels of zidovudine. Dose alterations should not be necessary.

Anti-infectives

↓Atovaquone

Ritonavir dosed as a pharmacokinetic enhancer induces glucuronidation and as a result is expected to decrease the plasma concentrations of atovaquone. Careful monitoring of serum levels or therapeutic effects is recommended when atovaquone is coadministered with ritonavir.

↑Bedaquiline

No interaction study is available with ritonavir only. Due to the risk of bedaquiline related adverse events, coadministration should be avoided. If the benefit outweighs the risk, coadministration of bedaquiline with ritonavir must be done with caution. More frequent electrocardiogram monitoring and monitoring of transaminases is recommended (see bedaquiline Summary

of Product Characteristics).

↑Clarithromycin (77%, 31%),

↓14-OH clarithromycin metabolite (100%, 99%)

Due to the large therapeutic window of clarithromycin no dose reduction should be necessary in patients with normal renal function. Clarithromycin doses greater than 1 g per day should not be coadministered with ritonavir dosed as a pharmacokinetic enhancer. For patients with renal impairment, a clarithromycin dose reduction should be considered: for patients with creatinine clearance of 30 to 60 mL/min the dose should be reduced by 50% (see section 4.2 for patients with severe renal impairment).

Delamanid

No interaction study is available with ritonavir only. In a healthy volunteer drug interaction study of delamanid 100 mg twice daily and lopinavir/ritonavir 400/100 mg twice daily for 14 days, the exposure of the delamanid metabolite DM‑6705 was 30% increased. Due to the risk of QTc prolongation associated with DM-6705, if coadministration of delamanid with ritonavir is considered necessary, very frequent ECG monitoring throughout the full Paxlovid treatment period is recommended (see section 4.4 and refer to the delamanid Summary of Product Characteristics).

↑Erythromycin,

↑Itraconazole*

↑Fusidic acid (systemic route)

Itraconazole increases AUC and C_max of nirmatrelvir by 39% and 19%, respectively. Ritonavir dosed as a pharmacokinetic enhancer inhibits CYP3A4 and as a result is expected to increase the plasma concentrations of itraconazole and erythromycin. Careful monitoring of therapeutic and adverse effects is recommended when erythromycin or itraconazole is coadministered with ritonavir.

Given the risk of substantial increase in fusidic acid (systemic route) exposure and thus of its related adverse events, coadministration should not be used unless a multidisciplinary consultation could be obtained to safely guide it.

↑Rifabutin (4-fold, 2.5-fold),

↑25-O-desacetyl rifabutin metabolite (38-fold, 16-fold)

Due to the large increase in rifabutin AUC, reduction of the rifabutin dose to 150 mg 3 times per week may be indicated when coadministered with ritonavir as a pharmacokinetic enhancer.

Rifampicin,

Rifapentine

Rifampicin and rifapentine are strong CYP3A4 inducers, and this may lead to a decreased exposure of nirmatrelvir/ritonavir, potential loss of virologic response and possible resistance. Concomitant use of rifampicin or rifapentine with Paxlovid is contraindicated (see section 4.3).

Sulfamethoxazole/trimethoprim

Dose alteration of sulfamethoxazole/trimethoprim during concomitant ritonavir therapy should not be necessary.

↓Voriconazole (39%, 24%)

Coadministration of voriconazole and ritonavir dosed as a pharmacokinetic enhancer should be avoided unless an assessment of the benefit/risk to the patient justifies the use of voriconazole.

Antipsychotics

↑Clozapine

Given the risk of substantial increase in clozapine exposure and thus of its related adverse events, coadministration should not be used unless a multidisciplinary consultation could be obtained to safely guide it.

↑Haloperidol,

↑Risperidone,

↑Thioridazine

Ritonavir is likely to inhibit CYP2D6 and as a result is expected to increase concentrations of haloperidol, risperidone and thioridazine. Careful monitoring of therapeutic and adverse effects is recommended when these medicines are concomitantly administered with antiretroviral doses of ritonavir.

↑Lurasidone

Due to CYP3A inhibition by ritonavir, concentrations of lurasidone are expected to increase. The concomitant administration with lurasidone is contraindicated (see section 4.3).

↑Pimozide

Ritonavir coadministration is likely to result in increased plasma concentrations of pimozide and is therefore contraindicated (see section 4.3).

↑Quetiapine

Due to CYP3A inhibition by ritonavir, concentrations of quetiapine are expected to increase. Concomitant administration of Paxlovid and quetiapine is contraindicated as it may increase quetiapine-related toxicity (see section 4.3).

Benign prostatic hyperplasia agents

↑Silodosin

Coadministration is contraindicated due to potential for postural hypotension (see section 4.3).

β2-agonist (long acting)

↑Salmeterol

Ritonavir inhibits CYP3A4 and as a result a pronounced increase in the plasma concentrations of salmeterol is expected, resulting in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations and sinus tachycardia. Therefore, avoid concomitant use with Paxlovid.

Calcium channel antagonists

↑Amlodipine,

↑Diltiazem,

↑Felodipine,

↑Nicardipine,

↑Nifedipine,

↑Verapamil

Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A4 and as a result is expected to increase the plasma concentrations of calcium channel antagonists. Careful monitoring of therapeutic and adverse effects is recommended when amlodipine, diltiazem, felodipine, nicardipine, nifedipine or verapamil are concomitantly administered with ritonavir.

↑Lercanidipine

Coadministration of lercanidipine and Paxlovid should be avoided.

Cardiovascular agents

↑Aliskiren

Avoid concomitant use with Paxlovid.

↑Cilostazol

Dosage adjustment of cilostazol is recommended. Refer to the cilostazol SmPC for more information.

Clopidogrel

Coadministration with clopidogrel may decrease levels of clopidogrel active metabolite. Avoid concomitant use with Paxlovid.

↑Eplerenone

Coadministration with eplerenone is contraindicated due to potential for hyperkalemia (see section 4.3).

↑Ivabradine

Coadministration with ivabradine is contraindicated due to potential for bradycardia or conduction disturbances (see section 4.3).

↑Ticagrelor

Given the risk of substantial increase in ticagrelor exposure and thus of its related adverse events, coadministration should not be used unless a multidisciplinary consultation could be obtained to safely guide it.

Cystic fibrosis transmembrane conductance regulator potentiators

↑Elexacaftor/ tezacaftor/ivacaftor,

↑Ivacaftor,

↑Tezacaftor/ivacaftor

Reduce dosage when coadministered with Paxlovid. Refer to individual SmPCs for more information.

Lumacaftor/ivacaftor

Coadministration contraindicated due to potential loss of virologic response and possible resistance (see section 4.3).

Dipeptidyl peptidase 4 (DPP4) inhibitors

↑Saxagliptin

Dosage adjustment of saxagliptin is recommended. Refer to the saxagliptin SmPC for more information.

Endothelin antagonists

↑Bosentan

Coadministration of bosentan and ritonavir may increase steady-state bosentan maximum concentrations (C_max) and AUC.

↑Riociguat

Serum concentrations may be increased due to CYP3A and P-gp inhibition by ritonavir. The coadministration of riociguat with Paxlovid is not recommended (refer to riociguat SmPC).

Ergot derivatives

↑Dihydroergotamine,

↑Ergonovine,

↑Ergotamine,

↑Methylergonovine

Ritonavir coadministration is likely to result in increased plasma concentrations of ergot derivatives and is therefore contraindicated (see section 4.3).

GI motility agent

↑Cisapride

Increased plasma concentrations of cisapride. Thereby, increasing the risk of serious arrhythmias from this agent and therefore concomitant use with Paxlovid is contraindicated (see section 4.3).

Herbal products

St. John’s Wort

Herbal preparations containing St John’s wort (Hypericum perforatum) due to the risk of decreased plasma concentrations and reduced clinical effects of nirmatrelvir and ritonavir and therefore concomitant use with Paxlovid is contraindicated (see section 4.3).

HMG Co-A reductase inhibitors

↑Atorvastatin,

Fluvastatin,

Lovastatin,

Pravastatin,

Rosuvastatin,

Simvastatin

HMG-CoA reductase inhibitors which are highly dependent on CYP3A metabolism, such as lovastatin and simvastatin, are expected to have markedly increased plasma concentrations when coadministered with ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer. Since increased concentrations of lovastatin and simvastatin may predispose patients to myopathies, including rhabdomyolysis, the combination of these medicinal products with ritonavir is contraindicated (see section 4.3). Atorvastatin is less dependent on CYP3A for metabolism. While rosuvastatin elimination is not dependent on CYP3A, an elevation of rosuvastatin exposure has been reported with ritonavir coadministration. The mechanism of this interaction is not clear, but may be the result of transporter inhibition. When used with ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent, the lowest possible doses of atorvastatin or rosuvastatin should be administered. The metabolism of pravastatin and fluvastatin is not dependent on CYP3A, and interactions are not expected with ritonavir. If treatment with an HMG-CoA reductase inhibitor is indicated, pravastatin or fluvastatin is recommended.

Hormonal contraceptive

↓Ethinyl Estradiol (40%, 32%)

Due to reductions in ethinyl estradiol concentrations, barrier or other non‑hormonal methods of contraception should be considered with concomitant ritonavir use when dosed as an antiretroviral agent or as a pharmacokinetic enhancer. Ritonavir is likely to change the uterine bleeding profile and reduce the effectiveness of estradiol-containing contraceptives.

Immunosuppressants

↑Voclosporin

Coadministration is contraindicated due to potential for acute and/or chronic nephrotoxicity (see section 4.3).

Immunosuppressants

Calcineurin inhibitors:

↑Cyclosporine,

↑Tacrolimus

mTOR inhibitors:

↑Everolimus,

↑Sirolimus

Ritonavir dosed as a pharmacokinetic enhancer inhibits CYP3A4 and as a result is expected to increase the plasma concentrations of cyclosporine, everolimus, sirolimus and tacrolimus. This coadministration should only be considered with close and regular monitoring of immunosuppressant serum concentrations, to reduce the dose of the immunosuppressant in accordance with the latest guidelines and to avoid over‑exposure and subsequent increase of serious adverse reactions of the immunosuppressant. It is important that the close and regular monitoring is performed not only during the coadministration with Paxlovid but is also pursued after the treatment with Paxlovid. As overall recommended for managing the drug-drug interaction, consultation of a multidisciplinary group is required to handle the complexity of this coadministration (see section 4.4).

Janus kinase (JAK) inhibitors

↑Tofacitinib

Dosage adjustment of tofacitinib is recommended. Refer to the tofacitinib SmPC for more information.

↑Upadacitinib

Dosing recommendations for coadministration of upadacitinib with Paxlovid depends on the upadacitinib indication. Refer to the upadacitinib SmPC for more information.

Lipid-modifying agents

↑Lomitapide

CYP3A4 inhibitors increase the exposure of lomitapide, with strong inhibitors increasing exposure approximately 27‑fold. Due to CYP3A inhibition by ritonavir, concentrations of lomitapide are expected to increase. Concomitant use of Paxlovid with lomitapide is contraindicated (see prescribing information for lomitapide) (see section 4.3).

Migraine medicinal products

↑Eletriptan

Coadministration of eletriptan within at least 72 hours of Paxlovid is contraindicated due to potential for serious adverse reactions including cardiovascular and cerebrovascular events (see section 4.3).

↑Rimegepant

Avoid concomitant use with Paxlovid.

Mineralocorticoid receptor antagonists

↑Finerenone

Coadministration contraindicated due to potential for serious adverse reactions including hyperkalemia, hypotension and hyponatremia (see section 4.3).

Muscarinic receptor antagonists

↑Darifenacin

Given the risk of substantial increase in darifenacin exposure and thus of its related adverse events, coadministration should not be used unless a multidisciplinary consultation could be obtained to safely guide it.

↑Solifenacine

Given the risk of substantial increase in solifenacine exposure and thus of its related adverse events, coadministration should not be used unless a multidisciplinary consultation could be obtained to safely guide it.

Neuropsychiatric

agents

↑Aripiprazole,

↑Brexpiprazole,

↑Cariprazine

Dosage adjustment of aripiprazole, brexpiprazole and cariprazine is recommended. Refer to individual SmPCs for more information.

Opioid antagonists

↑Naloxegol

Coadministration contraindicated due to the potential for opioid withdrawal symptoms (see section 4.3).

Phosphodiesterase (PDE5) inhibitors

↑Avanafil (13-fold, 2.4-fold)

↑Sildenafil (11-fold, 4-fold)

↑Tadalafil (124%, ↔)

↑Vardenafil (49-fold, 13-fold)

Concomitant use of avanafil, sildenafil, tadalafil and vardenafil with Paxlovid is contraindicated (see section 4.3).

Sedatives/hypnotics

↑Alprazolam (2.5-fold, ↔)

Alprazolam metabolism is inhibited following the introduction of ritonavir. Caution is warranted during the first several days when alprazolam is coadministered with ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer, before induction of alprazolam metabolism develops.

↑Buspirone

Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A and as a result is expected to increase the plasma concentrations of buspirone. Careful monitoring of therapeutic and adverse effects is recommended when buspirone concomitantly administered with ritonavir.

↑Clorazepate,

↑Diazepam,

↑Estazolam,

↑Flurazepam

Ritonavir coadministration is likely to result in increased plasma concentrations of clorazepate, diazepam, estazolam, and flurazepam and is therefore contraindicated (see section 4.3).

↑Oral Midazolam (1330%, 268%)* and parenteral Midazolam

Midazolam is extensively metabolised by CYP3A4. Coadministration with Paxlovid may cause a large increase in the concentration of midazolam. Plasma concentrations of midazolam are expected to be significantly higher when midazolam is given orally. Therefore, coadministration of Paxlovid with orally administered midazolam is contraindicated (see section 4.3), whereas caution should be used with coadministration of Paxlovid and parenteral midazolam. Data from concomitant use of parenteral midazolam with other protease inhibitors suggests a possible 3- to 4-fold increase in midazolam plasma levels. If Paxlovid is coadministered with parenteral midazolam, it should be done in an intensive care unit (ICU) or similar setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. Dosage adjustment for midazolam should be considered, especially if more than a single dose of midazolam is administered.

↑Triazolam (> 20-fold, 87%)

Ritonavir coadministration is likely to result in increased plasma concentrations of triazolam and is therefore contraindicated (see section 4.3).

Sleeping agent

↑Zolpidem (28%, 22%)

Zolpidem and ritonavir may be coadministered with careful monitoring for excessive sedative effects.

Smoke cessation

↓Bupropion (22%, 21%)

Bupropion is primarily metabolised by CYP2B6. Concurrent administration of bupropion with repeated doses of ritonavir is expected to decrease bupropion levels. These effects are thought to represent induction of bupropion metabolism. However, because ritonavir has also been shown to inhibit CYP2B6 in vitro, the recommended dose of bupropion should not be exceeded. In contrast to long-term administration of ritonavir, there was no significant interaction with bupropion after short‑term administration of low doses of ritonavir (200 mg twice daily for 2 days), suggesting reductions in bupropion concentrations may have onset several days after initiation of ritonavir coadministration.

Steroids

Budesonide,

Inhaled, injectable or intranasal fluticasone propionate,

Triamcinolone

Systemic corticosteroid effects including Cushing's syndrome and adrenal suppression (plasma cortisol levels were noted to be decreased 86%) have been reported in patients receiving ritonavir and inhaled or intranasal fluticasone propionate; similar effects could also occur with other corticosteroids metabolised by CYP3A e.g., budesonide and triamcinolone. Consequently, concomitant administration of ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer and these glucocorticoids is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects. A dose reduction of the glucocorticoid should be considered with close monitoring of local and systemic effects or a switch to a glucocorticoid, which is not a substrate for CYP3A4 (e.g., beclomethasone). Moreover, in case of withdrawal of glucocorticoids progressive dose reduction may be required over a longer period.

↑Dexamethasone

Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A and as a result is expected to increase the plasma concentrations of dexamethasone. Careful monitoring of therapeutic and adverse effects is recommended when dexamethasone is concomitantly administered with ritonavir.

↑Prednisolone (28%, 9%)

Careful monitoring of therapeutic and adverse effects is recommended when prednisolone is concomitantly administered with ritonavir. The AUC of the metabolite prednisolone increased by 37% and 28% after 4 and 14 days ritonavir, respectively.

Thyroid hormone replacement therapy

Levothyroxine

Post-marketing cases have been reported indicating a potential interaction between ritonavir containing products and levothyroxine. Thyroid-stimulating hormone (TSH) should be monitored in patients treated with levothyroxine at least the first month after starting and/or ending ritonavir treatment.

Vasopressin receptor antagonists

↑Tolvaptan

Coadministration is contraindicated due to potential for dehydration, hypovolemia and hyperkalemia (see section 4.3).

Abbreviations: ATL=alanine aminotransferase; AUC=area under the curve.

* Results from DDI studies conducted with Paxlovid.

Immune system disorders

Uncommon

Hypersensitivity

Rare

Anaphylaxis

Nervous system disorders

Common

Dysgeusia, headache

Vascular disorders

Uncommon

Hypertension

Gastrointestinal disorders

Common

Diarrhoea, vomiting, nausea

Uncommon

Abdominal pain

Skin and subcutaneous tissue disorders

Uncommon

Rash*

Rare

Toxic epidermal necrolysis, Stevens-Johnson syndrome,

Pruritus*

Musculoskeletal and connective tissue disorders

Uncommon

Myalgia

General disorders and administration site conditions

Rare

Malaise

National Pharmacovigilance Center (NPC)

Call center: 19999

E-mail: npc.drug@sfda.gov.sa

Website: https://ade.sfda.gov.sa/  

-   Please contact the relevant competent authority.

Table 3:     SARS-CoV-2 M^pro amino acid substitutions selected by nirmatrelvir in cell culture (with EC₅₀ fold change >5)

S144A (2.2-5.3), E166V (25-288), P252L (5.9), T304I (1.4-5.5), T21I+S144A (9.4), T21I+E166V (83), T21I+T304I (3.0-7.9), L50F+E166V (34-175), L50F+T304I (5.9), F140L+A173V (10.1), A173V+T304I (20.2), T21+L50F+A193P+S301P (28.8), T21I+S144A+T304I (27.8), T21I+C160F+A173V+V186A+T304I (28.5), T21I+A173V+T304I (15), L50F+F140L+L167F+T304I (54.7)

Paxlovid

(N=977)

Placebo

(N=989)

COVID-19 related hospitalisation or death from any cause through Day 28

n (%)

9 (0.9%)

64 (6.5%)

Reduction relative to placebo^a (95% CI), %

-5.64 (-7.31, -3.97)

p-value

< 0.0001

All-cause mortality through Day 28, %

0

12 (1.2%)

Abbreviations: CI=confidence interval; COVID-19=Coronavirus Disease 2019; mAb=monoclonal antibody; mITT1=modified intent-to-treat 1 (all participants randomly assigned to study intervention, who took at least 1 dose of study intervention, with at least 1 post-baseline visit through Day 28, who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment and were treated ≤ 5 days after COVID-19 symptom onset).

a.     The estimated cumulative proportion of participants hospitalised or death by Day 28 was calculated for each treatment group using the Kaplan-Meier method, where participants without hospitalisation and death status through Day 28 were censored at the time of study discontinuation.

b.     Data analysis set was updated after post-hoc removal of data for 133 participants due to GCP quality issues

Paxlovid 300 mg/100 mg

Placebo

Number of patients

N=977

N=989

Serology Negative

n=475

n=497

Patients with hospitalisation or death^a (%)

Estimated proportion over 28 days [95% CI], %

  Estimated reduction relative to placebo (95% CI)

8 (1.7%)

1.72 (0.86, 3.40)

-9.79 (-12.86, -6.72)

56 (11.3%)

11.50 (8.97, 14.68)

Serology Positive

n=490

n=479

Patients with hospitalisation or death^a (%)

Estimated proportion over 28 days [95% CI], %

  Estimated reduction relative to placebo (95% CI)

1 (0.2%)

0.20 (0.03, 1.44)

-1.5 (-2.70, -0.25)

8 (1.7%)

1.68 (0.84, 3.33)

Abbreviations: CI=confidence interval; COVID-19=Coronavirus Disease 2019; mITT1=modified intent‑to‑treat 1 (all participants randomly assigned to study intervention, who took at least 1 dose of study intervention, who at baseline did not receive nor were expected to receive COVID‑19 therapeutic monoclonal antibody treatment, and were treated ≤ 5 days after COVID-19 symptom onset).

Seropositivity was defined if results were positive in a serological immunoassay specific for host antibodies to either S or N viral proteins.

The difference between the proportions in the 2 treatment groups and its 95% confidence interval based on normal approximation of the data are presented.

a.       COVID-19 related hospitalisation or death from any cause.

Table 3:     SARS-CoV-2 M^pro amino acid substitutions selected by nirmatrelvir in cell culture (with EC₅₀ fold change >5)

S144A (2.2-5.3), E166V (25-288), P252L (5.9), T304I (1.4-5.5), T21I+S144A (9.4), T21I+E166V (83), T21I+T304I (3.0-7.9), L50F+E166V (34-175), L50F+T304I (5.9), F140L+A173V (10.1), A173V+T304I (20.2), T21+L50F+A193P+S301P (28.8), T21I+S144A+T304I (27.8), T21I+C160F+A173V+V186A+T304I (28.5), T21I+A173V+T304I (15), L50F+F140L+L167F+T304I (54.7)

Paxlovid

(N=977)

Placebo

(N=989)

COVID-19 related hospitalisation or death from any cause through Day 28

n (%)

9 (0.9%)

64 (6.5%)

Reduction relative to placebo^a (95% CI), %

-5.64 (-7.31, -3.97)

p-value

< 0.0001

All-cause mortality through Day 28, %

0

12 (1.2%)

Abbreviations: CI=confidence interval; COVID-19=Coronavirus Disease 2019; mAb=monoclonal antibody; mITT1=modified intent-to-treat 1 (all participants randomly assigned to study intervention, who took at least 1 dose of study intervention, with at least 1 post-baseline visit through Day 28, who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment and were treated ≤ 5 days after COVID-19 symptom onset).

a.     The estimated cumulative proportion of participants hospitalised or death by Day 28 was calculated for each treatment group using the Kaplan-Meier method, where participants without hospitalisation and death status through Day 28 were censored at the time of study discontinuation.

b.     Data analysis set was updated after post-hoc removal of data for 133 participants due to GCP quality issues

Paxlovid 300 mg/100 mg

Placebo

Number of patients

N=977

N=989

Serology Negative

n=475

n=497

Patients with hospitalisation or death^a (%)

Estimated proportion over 28 days [95% CI], %

  Estimated reduction relative to placebo (95% CI)

8 (1.7%)

1.72 (0.86, 3.40)

-9.79 (-12.86, -6.72)

56 (11.3%)

11.50 (8.97, 14.68)

Serology Positive

n=490

n=479

Patients with hospitalisation or death^a (%)

Estimated proportion over 28 days [95% CI], %

  Estimated reduction relative to placebo (95% CI)

1 (0.2%)

0.20 (0.03, 1.44)

-1.5 (-2.70, -0.25)

8 (1.7%)

1.68 (0.84, 3.33)

Abbreviations: CI=confidence interval; COVID-19=Coronavirus Disease 2019; mITT1=modified intent‑to‑treat 1 (all participants randomly assigned to study intervention, who took at least 1 dose of study intervention, who at baseline did not receive nor were expected to receive COVID‑19 therapeutic monoclonal antibody treatment, and were treated ≤ 5 days after COVID-19 symptom onset).

Seropositivity was defined if results were positive in a serological immunoassay specific for host antibodies to either S or N viral proteins.

The difference between the proportions in the 2 treatment groups and its 95% confidence interval based on normal approximation of the data are presented.

a.       COVID-19 related hospitalisation or death from any cause.